MMA Embolization for Refractory Chronic Migraine
NCT06735833
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a prospective, multi-center, feasibility study to investigate safety and effectiveness of TRUFILL n-BCA liquid embolic system in bilateral middle meningeal artery (MMA) embolization for the treatment of refractory chronic migraine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Migraine Disorders
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Cerenovus, Part of DePuy Synthes Products, Inc.
- Last updated on ClinicalTrials.gov
- September 25, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- John Muir Physician Network Clin. Research Center · Walnut Creek, CA
Connecticut · 1
- Hartford Hospital · Hartford, CT
New York · 3
- University of Buffalo Medical Center · Buffalo, NY
- Mount Sinai · New York, NY
- Stony Brook University Medical Center · Stony Brook, NY
Pennsylvania · 1
- Thomas Jefferson University Hospital · Philadelphia, PA
Tennessee · 1
- Semmes Murphey Foundation · Memphis, TN
West Virginia · 1
- West Virginia University · Morgantown, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.